Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
19.3M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
152M
-
Shares change
-
+2.16M
-
Total reported value, excl. options
-
$81.8M
-
Value change
-
+$816K
-
Put/Call ratio
-
2.07
-
Number of buys
-
37
-
Number of sells
-
-40
-
Price
-
$0.54
Significant Holders of Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) as of Q1 2025
118 filings reported holding LYEL - Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share as of Q1 2025.
Lyell Immunopharma, Inc. - Common Stock, par value $0.0001 per share (LYEL) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 152M shares
.
Largest 10 shareholders include MWG Management Ltd. (20.2M shares), Foresite Capital Management IV, LLC (16M shares), Orland Properties Ltd (15.1M shares), BlackRock, Inc. (12.7M shares), Decheng Capital LLC (11.9M shares), VANGUARD GROUP INC (9.74M shares), Foresite Capital Management V, LLC (8.13M shares), venBio Partners LLC (7.1M shares), PRICE T ROWE ASSOCIATES INC /MD/ (6.48M shares), and Alphabet Inc. (5.87M shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.